Study of ARO-APOC3 in Adults With Dyslipidemia

Conditions

• Dyslipidemias

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• ARO-APOC3 — DRUG
  ARO-APOC3 Injection

Study Details

This is an open-label extension of the parent studies AROAPOC3-2001 and AROAPOC3-2002. Adult participants with dyslipidemia who completed the blinded 12-month period from either parent study and continued to meet eligibility criteria had the option to be enrolled into this study. Eligible enrolled participants initially received open-label ARO-APOC3 every three or six months at the assigned dose level of the parent study until a final dose of 25 mg was selected, at which point all participants transitioned to the selected dosing regimen of 25 mg every 3 months.

Key Dates

Start date

Jul 7, 2022

Status verified

May 2026

Primary completion

Sep 22, 2025

Completion

Sep 22, 2025

Study Design

Enrollment

418 participants (actual)

Allocation

NA

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Arms

• Experimental: ARO-APOC3
  1 dose of ARO-APOC3 by subcutaneous (sc) injection every 3 months

Primary Outcome Measure

Number of Participants with Treatment-Emergent Adverse Events (TEAEs) [ Time Frame: Through 24 months ]

Locations (30)

Find similar trials in Beverly Hills, CA

Related Studies

• Gut Microbiota in Metabolic Surgery
  Recruiting · Vanderbilt University Medical Center · Nashville, Tennessee
• Addressing Barriers to Achieving Cardiometabolic Disorders Prevention and Treatment Goals for PLWH in the SE US
  Recruiting · Duke University · Charlotte, North Carolina
• Cholesterol and Inflammation Lowering Via Bempedoic Acid, an ACL-inhibiting Regimen in HIV Trial (CLEAR HIV Trial)
  PHASE2 · Recruiting · Priscilla Hsue, MD · Los Angeles, California
• A Safety and Tolerability Trial Evaluating CTX310 in Participants With Refractory Dyslipidemias
  PHASE1 · Recruiting · CRISPR Therapeutics AG · Jacksonville, Florida